Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition
Completed
Fresenius Kabi
Phase 3
2007-10-01
The aim of this study is to evaluate the safety and tolerance of SMOFlipid 20% in comparison
to a standard lipid emulsion Intralipid 20% in patients requiring long-term parenteral
nutrition. The safety and tolerance will be evaluated by biochemistry, hematology and
coagulation variables, vital signs and adverse events. Further objectives to evaluate are the
influence of SMOFlipid 20% on inflammation processes, the efficacy of anti-oxidative
properties of vitamin E supplemented to SMOFlipid 20%, and the fatty acid pattern in red
blood cells and serum.
Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?
Unknown status
Fresenius Kabi
Phase 2
2009-01-01
The aim of this study is to determine the feasibility of conducting a trial to examine the
efficacy of an ω3FA (Omega-3 fatty acid) containing balanced lipid emulsion in the prevention
of progression of PNALD in infants with Intestinal Failure/Short Bowel Syndrome (SBS) and
early liver dysfunction.
Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?
Unknown status
The Hospital for Sick Children
Phase 2
2009-01-01
The aim of this study is to determine the feasibility of conducting a trial to examine the
efficacy of an ω3FA (Omega-3 fatty acid) containing balanced lipid emulsion in the prevention
of progression of PNALD in infants with Intestinal Failure/Short Bowel Syndrome (SBS) and
early liver dysfunction.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
